KP Tissue Inc. (KPT) (TSX: KPT) reports the Q3 2024 financial and
operational results of KPT and Kruger Products Inc. (Kruger
Products). Kruger Products is Canada's leading manufacturer of
quality tissue products for the Consumer market (Cashmere®, Purex®,
SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the
Away-From-Home (AFH) market and continues to grow in the U.S.
Consumer tissue business with the White Cloud® brand and premium
private label products. KPT currently holds a 12.6% interest in
Kruger Products.
Kruger Products Q3 2024 Business and Financial
Highlights
- Revenue was $521.1 million in Q3 2024
compared to $473.4 million in Q3 2023, an increase of $47.7 million
or 10.1%.
- Adjusted EBITDA1 was $65.7 million in
Q3 2024, compared to $72.4 million in Q3 2023, a decrease of
9.3%.
- Net income was $18.0 million in Q3
2024 compared to $12.9 million in Q3 2023, an increase of $5.1
million.
- Declared a quarterly dividend of
$0.18 per share to be paid on January 15, 2025.
“Our business continued to perform well with
double-digit revenue growth in the third quarter of 2024 on the
strength of higher sales volume and favourable selling prices
across our North American network,” stated KP Tissue’s Chief
Executive Officer, Dino Bianco. “Despite higher pulp prices and
other manufacturing costs year-over-year, we generated solid
Adjusted EBITDA of $65.7 million that was within our expectations.
In the Consumer segment, we maintained strong revenue momentum
through ongoing investments in innovation and brand support. The
resulting impact has been highly encouraging with our leadership
position rising above 44% in the Canadian facial tissue market,
combined with share gains in the bathroom tissue and paper towel
categories on a year-over-year basis. On the Away-from-Home front,
sales volume slightly improved in the third quarter of 2024
compared to the same period in 2023, while profitability was
tempered by additional outsourcing activity.”
“The operational highlight of the quarter was
the completed construction of our manufacturing plant in
Sherbrooke, including the successful start-up of our LDC paper
machine with added capacity of 60,000 metric tons. At maturity, the
entire Sherbrooke site, which also contains the existing TAD
facility along with recently deployed LDC facial tissue and
bathroom tissue lines, will produce more than 130,000 metric tons
of high-quality tissue products. As a result, we are fulfilling our
vision of making Sherbrooke a major hub for tissue manufacturing,
enabling additional share gains in North America and reducing our
need for purchased paper,” Mr. Bianco added.
Outlook for Q4 2024For the last quarter of
2024, we expect Adjusted EBITDA1 to be in the range of Q3 2024.
Kruger Products Q3 2024 Financial
ResultsRevenue was $521.1 million in Q3 2024 compared to
$473.4 million in Q3 2023, an increase of $47.7 million or 10.1%.
The increase in revenue was primarily due to higher sales volume
and favourable selling prices across both segments. Revenue was
also favourably impacted by foreign exchange fluctuations on U.S.
dollar sales.
Cost of sales was $437.3 million in Q3 2024
compared to $386.3 million in Q3 2023, an increase of $51.0 million
or 13.2%. The increase in cost of sales was primarily due to higher
sales volume and pulp prices, additional outsourcing activity
compared to Q3 2023 and the unfavourable impact of foreign exchange
fluctuations on U.S. dollar costs, partially offset by lower
manufacturing overhead costs due primarily to overhead cost
absorption resulting from higher inventory levels in the quarter.
Freight rates were higher compared to Q3 2023, while warehousing
costs increased slightly as a result of handling costs related to
higher sales volume. As a percentage of revenue, cost of sales was
83.9% in Q3 2024 compared to 81.6% in Q3 2023.
Selling, general and administrative (SG&A)
expenses were $46.5 million in Q3 2024 compared to $40.0 million in
Q3 2023, an increase of $6.5 million or 16.3%. The increase was
primarily due to additional investment in advertising and
promotion, consulting and legal costs to support operational and
corporate initiatives, higher selling expense to primarily support
additional sales volume, higher IT spend and foreign exchange
losses in Q3 2024 compared to gains in the year ago quarter. As a
percentage of revenue, SG&A expenses were 8.9% in Q3 2024
compared to 8.4% in Q3 2023.
Adjusted EBITDA1 was $65.7 million in Q3 2024
compared to $72.4 million in Q3 2023, a decrease of $6.7 million or
9.3%. The decrease was primarily due to higher pulp prices and
other manufacturing costs as described above, along with higher
freight rates and SG&A expenses, partially offset by higher
sales volumes and selling prices along with lower manufacturing
overhead costs.
Net income was $18.0 million in Q3 2024 compared
to $12.9 million in Q3 2023, an increase of $5.1 million. The
increase was primarily due to a higher foreign exchange gain and
lower income tax expense, partially offset by lower Adjusted
EBITDA1, higher depreciation expense and higher interest expense
and other finance costs.
Kruger Products Q3 2024 Financing
Activity and LiquidityOn November 1, 2024, Kruger Products
issued $135 million in an aggregate principal amount of 6.625%
Senior Unsecured Notes (the Notes) due November 1, 2031 through a
private placement. Interest on the Notes is payable semi-annually
in arrears on May 1 and November 1 of each year, commencing on May
1, 2025. The majority of the proceeds were used to redeem the $125
million Senior Unsecured Notes with the remainder being used for
general corporate purposes.
Kruger Products completed the previously
announced redemption of its outstanding $125 million principal
amount of 6.0% Senior Unsecured Notes on November 12, 2024 at a
redemption price of 100% of the principal amount plus accrued and
unpaid interest.
Total liquidity, representing cash and
availability under the revolving credit agreements, was $434.2
million as of September 30, 2024. In addition, $14.6 million of
cash was held for the Sherbrooke Expansion Project.
KPT Q3 2024 Financial
ResultsKPT had net income of $2.1 million in Q3 2024.
Included in net income was $2.3 million representing KPT’s share of
Kruger Products’ net income, a dilution gain of $0.1 million and
depreciation expense of $0.3 million related to adjustments to
carrying amounts on acquisition.
Dividends on Common SharesThe Board of
Directors of KPT declared a quarterly dividend of $0.18 per share
to be paid on January 15, 2025 to shareholders of record at the
close of business on December 31, 2024.
Additional InformationFor
additional information please refer to Management’s Discussion and
Analysis (MD&A) of KPT and Kruger Products for the third
quarter ended September 30, 2024 available on SEDAR+ at
www.sedarplus.ca or our website
at www.kptissueinc.com.
Third Quarter Results Conference Call
InformationKPT will hold its third quarter conference call
on Wednesday, November 13, 2024 at 8:30 a.m. Eastern Time.
Via telephone: 1-888-510-2154 or 437-900-0527
Via the internet at: www.kptissueinc.com
Presentation material referenced during the conference call will
be available at www.kptissueinc.com.
A rebroadcast of the conference call will be
available until midnight, November 20, 2024 by dialing
1-888-660-6345 or 289-819-1450 and entering passcode 96818.
The replay of the webcast will remain available on the website
until midnight, November 20, 2024.
About KP Tissue Inc.KPT was
created to acquire, and its business is limited to holding, a
limited equity interest in Kruger Products, which is accounted for
as an investment on the equity basis. KPT currently holds a 12.6%
interest in Kruger Products. For more information visit
www.kptissueinc.com.
About Kruger Products
Inc.Kruger Products is Canada's leading manufacturer of
quality tissue products for household, industrial and commercial
use. Kruger Products serves the Canadian consumer market with such
well-known brands as Cashmere®, Purex®, SpongeTowels®, Scotties®,
White Swan® and BonterraTM. In the U.S., Kruger Products
manufactures the White Cloud® brand, as well as many private label
products. The Away-From-Home division manufactures and distributes
high-quality, cost-effective product solutions to a wide range of
commercial and public entities. Kruger Products has approximately
3,000 employees and operates nine FSC® COC-certified (FSC®
C-104904) production facilities in North America. For more
information visit www.krugerproducts.ca.
Non-GAAP Financial MeasuresThis
press release uses certain non-GAAP financial measures which Kruger
Products believes provide useful information to management of
Kruger Products and the readers of the financial information in
measuring the financial performance and financial condition of
Kruger Products. These measures do not have a standardized meaning
prescribed by GAAP and therefore may not be comparable to similarly
titled measures presented by other companies. An example of such a
measure is Adjusted EBITDA. Adjusted EBITDA is not a measurement of
operating performance computed in accordance with GAAP and should
not be considered as a substitute for operating income, net income
or cash flows from operating activities computed in accordance with
GAAP. “Adjusted EBITDA” is calculated by Kruger Products as net
income (loss) before (i) interest expense and other finance costs,
(ii) income taxes, (iii) depreciation, (iv) amortization, (v) loss
on sale of non-financial assets, (vi) loss (gain) on disposal of
property, plant and equipment, (vii) foreign exchange loss (gain),
(viii) costs related to restructuring activities and (ix) changes
in amortized cost of Partnership units liability. A reconciliation
of Adjusted EBITDA to the relevant reported results can be found in
the Segment and Geographic Results table of this news release.
Forward-Looking
StatementsCertain statements in this press release about
KPT’s and Kruger Products' current and future plans, expectations
and intentions, results, levels of activity, performance, goals or
achievements or any other future events or developments constitute
forward-looking statements. The words "may", "will", "would",
"should", "could", "expects", "plans", "intends", "trends",
"indications", "anticipates", "believes", "estimates", "predicts",
"likely" or "potential" or the negative or other variations of
these words or other comparable words or phrases, are intended to
identify forward-looking statements. The forward-looking statements
are based on certain key expectations and assumptions made by KPT
or Kruger Products, including the moderation of inflationary
pressure on input costs and continued inflationary pressure on
SG&A as labour, marketing and IT costs continue to rise.
Although KPT and Kruger Products believe that the expectations and
assumptions on which such forward-looking information is based are
reasonable, undue reliance should not be placed on the
forward-looking statements since no assurance can be given that
such expectations and assumptions will prove to be correct.
The outlook provided in respect of Adjusted
EBITDA1 for Q4 2024 is forward-looking information and is based on
the assumptions and subject to the risk and uncertainties referred
to below. The purpose of the outlook is to provide the reader with
an indication of management’s expectations, at the date of this
press release, regarding Kruger Products’ future financial
performance. Readers are cautioned that this information may not be
appropriate for other purposes.
Many factors could cause Kruger Products’ actual
results, level of activity, performance or achievements or future
events or developments (which could in turn affect the economic
benefits derived from KPT’s economic interest in Kruger Products),
to differ materially from those expressed or implied by the
forward-looking statements, including, without limitation, the
following factors, which are discussed in greater detail in the
“Risk Factors – Risks Related to Kruger Products’ Business” section
of the KPT Annual Information Form dated March 7, 2024 available on
SEDAR+ at www.sedarplus.ca Kruger Inc.’s influence over
Kruger Products; Kruger Products’ reliance on Kruger Inc.;
consequences of an event of insolvency relating to Kruger Inc.;
risks associated with the ownership of the TAD Sherbrooke Project;
risks associated with the operation of the TAD Sherbrooke Project;
risks associated with the Sherbrooke Expansion Project; operational
risks; significant increases in input costs; reduction in supply of
fibre; increased pricing pressure and intense competition; Kruger
Products’ inability to innovate effectively; adverse economic
conditions; dependence on key retail trade customers; damage to the
reputation of Kruger Products or Kruger Products’ brands; Kruger
Products’ sales being less than anticipated; Kruger Products’
failure to implement its business and operating strategies; Kruger
Products’ obligation to make regular capital expenditures; Kruger
Products entering into unsuccessful acquisitions; Kruger Products’
dependence on key personnel; Kruger Products’ inability to retain
its existing customers or obtain new customers; Kruger Products’
loss of key suppliers; Kruger Products’ failure to adequately
protect its intellectual property rights; Kruger Products’ reliance
on third party intellectual property licenses; adverse litigation
and other claims affecting Kruger Products; material expenditures
due to comprehensive environmental regulation affecting Kruger
Products’ cash flow; Kruger Products’ pension obligations are
significant and can be materially higher than predicted if Kruger
Products Management’s underlying assumptions are incorrect; labour
disputes adversely affecting Kruger Products’ cost structure and
Kruger Products’ ability to run its plants; exchange rate and U.S.
competitors; Kruger Products’ inability to service all of its
indebtedness; exposure to potential consumer product liability;
covenant compliance; interest rate and refinancing risk; and risks
relating to information technology; cyber-security; insurance;
internal controls; and trade.
Readers should not place undue reliance on
forward-looking statements made herein. The forward-looking
information contained herein is expressly qualified in its entirety
by this cautionary statement. The forward-looking information
contained herein is made as of the date of press release and KPT
undertakes no obligation to publicly update such forward-looking
information to reflect new information, subsequent or otherwise,
unless required by applicable securities laws.
INFORMATION:Francois ParoyanGeneral Counsel and
Corporate SecretaryKP Tissue
Inc.905-812-6936francois.paroyan@krugerproducts.ca
INVESTORS:Doris GrbicDirector, Investor
RelationsKP Tissue Inc.437-882-2596IR@krugerproducts.ca
1 Adjusted EBITDA is a non-GAAP financial
measure. Refer to the Non-GAAP Financial Measures section of this
news release for more information on these measures
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements of Financial
Position |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2024 |
|
|
December 31, 2023 |
|
|
|
$ |
|
|
$ |
|
Assets |
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
111,215 |
|
|
135,728 |
|
|
Restricted cash |
44,832 |
|
|
12,451 |
|
|
Trade and other receivables |
142,468 |
|
|
130,157 |
|
|
Receivables from related parties |
80 |
|
|
842 |
|
|
Inventories |
262,343 |
|
|
254,372 |
|
|
Income tax recoverable |
9,384 |
|
|
4,578 |
|
|
Prepaid expenses |
13,998 |
|
|
4,726 |
|
|
|
584,320 |
|
|
542,854 |
|
Non-current assets |
|
|
|
|
Property, plant and equipment |
1,473,638 |
|
|
1,421,650 |
|
|
Right-of-use assets |
149,445 |
|
|
84,866 |
|
|
Other long-term assets |
52 |
|
|
3,808 |
|
|
Pensions |
89,109 |
|
|
69,839 |
|
|
Goodwill |
152,021 |
|
|
152,021 |
|
|
Intangible assets |
40,973 |
|
|
26,852 |
|
|
Deferred income taxes |
5,679 |
|
|
23,740 |
|
Total assets |
2,495,237 |
|
|
2,325,630 |
|
|
|
|
|
|
Liabilities |
|
|
|
Current liabilities |
|
|
|
|
Trade and other payables |
353,616 |
|
|
400,385 |
|
|
Payables to related parties |
14,364 |
|
|
10,973 |
|
|
Income tax payable |
40 |
|
|
- |
|
|
Dividends payable |
14,173 |
|
|
13,675 |
|
|
Current portion of long-term debt |
169,918 |
|
|
35,229 |
|
|
Current portion of lease liabilities |
39,774 |
|
|
27,154 |
|
|
Current portion of long-term payable to related party |
5,800 |
|
|
5,800 |
|
|
Current portion of provisions |
3,728 |
|
|
3,952 |
|
|
|
601,413 |
|
|
497,168 |
|
Non-current liabilities |
|
|
|
|
Long-term debt |
997,478 |
|
|
1,034,016 |
|
|
Long-term lease liabilities |
127,194 |
|
|
71,865 |
|
|
Long-term payable to related party |
31,411 |
|
|
35,580 |
|
|
Long-term provisions |
6,015 |
|
|
5,740 |
|
|
Pensions |
14,692 |
|
|
18,935 |
|
|
Post-retirement benefits |
50,038 |
|
|
48,699 |
|
Total liabilities |
1,828,241 |
|
|
1,712,003 |
|
|
|
|
|
|
Equity |
|
|
|
|
Share capital |
302,328 |
|
|
278,252 |
|
|
Contributed surplus |
395,382 |
|
|
395,382 |
|
|
Deficit |
(147,962 |
) |
|
(164,029 |
) |
|
Accumulated other comprehensive income |
85,640 |
|
|
81,011 |
|
|
Equity attributable to Kruger Products |
635,388 |
|
|
590,616 |
|
|
Non-controlling interest |
31,608 |
|
|
23,011 |
|
Total equity |
666,996 |
|
|
613,627 |
|
Total equity and liabilities |
2,495,237 |
|
|
2,325,630 |
|
|
|
|
|
|
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements
of Income (Loss) |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended September 30, 2024 |
|
|
3-month period ended September 30, 2023 |
|
|
9-month period ended September 30, 2024 |
|
|
9-month period ended September 30, 2023 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
Revenue |
521,085 |
|
|
473,399 |
|
|
1,510,317 |
|
|
1,390,693 |
|
|
|
|
|
|
|
|
|
|
|
Expenses |
|
|
|
|
|
|
|
|
|
Cost of sales |
437,202 |
|
|
386,375 |
|
|
1,262,433 |
|
|
1,171,111 |
|
Selling, general and administrative expenses |
46,533 |
|
|
39,973 |
|
|
133,145 |
|
|
116,890 |
|
Restructuring costs, net |
- |
|
|
77 |
|
|
219 |
|
|
1,300 |
|
|
|
|
|
|
|
|
|
|
|
Operating income |
37,350 |
|
|
46,974 |
|
|
114,520 |
|
|
101,392 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense and other finance costs |
17,997 |
|
|
16,677 |
|
|
51,132 |
|
|
51,740 |
|
Other expense (income) |
(5,266 |
) |
|
8,395 |
|
|
7,152 |
|
|
(870 |
) |
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
24,619 |
|
|
21,902 |
|
|
56,236 |
|
|
50,522 |
|
|
|
|
|
|
|
|
|
|
|
Current tax expense |
1,768 |
|
|
515 |
|
|
3,149 |
|
|
1,943 |
|
Deferred tax expense |
3,244 |
|
|
6,553 |
|
|
11,723 |
|
|
68,860 |
|
|
|
|
|
|
|
|
|
|
|
Income tax expense |
5,012 |
|
|
7,068 |
|
|
14,872 |
|
|
70,803 |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) including non-controlling
interest |
19,607 |
|
|
14,834 |
|
|
41,364 |
|
|
(20,281 |
) |
|
|
|
|
|
|
|
|
|
|
Net income attributable to non-controlling
interest |
1,614 |
|
|
1,906 |
|
|
3,823 |
|
|
1,568 |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to Kruger
Products |
17,993 |
|
|
12,928 |
|
|
37,541 |
|
|
(21,849 |
) |
|
|
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Unaudited Condensed Consolidated Statements of Cash
Flows |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended September 30, 2024 |
|
|
3-month period ended September 30, 2023 |
|
|
9-month period ended September 30, 2024 |
|
|
9-month period ended September 30, 2023 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Cash flows from (used in) operating
activities |
|
|
|
|
|
|
|
Net income (loss) including non-controlling interest |
19,607 |
|
|
14,834 |
|
|
41,364 |
|
|
(20,281 |
) |
Items not affecting cash |
|
|
|
|
|
|
|
Depreciation |
26,561 |
|
|
24,227 |
|
|
78,688 |
|
|
70,305 |
|
Amortization |
1,739 |
|
|
1,110 |
|
|
4,300 |
|
|
3,271 |
|
Loss (gain) on sale of property, plant and equipment |
- |
|
|
(11 |
) |
|
269 |
|
|
1,098 |
|
Gain on disposal of leased assets |
- |
|
|
- |
|
|
- |
|
|
(488 |
) |
Foreign exchange loss (gain) |
(5,266 |
) |
|
8,395 |
|
|
8,033 |
|
|
(870 |
) |
Interest expense and other finance costs |
17,997 |
|
|
16,677 |
|
|
51,132 |
|
|
51,740 |
|
Pension and post-retirement benefits |
3,680 |
|
|
2,344 |
|
|
8,964 |
|
|
6,456 |
|
Provisions |
1,297 |
|
|
765 |
|
|
3,415 |
|
|
2,704 |
|
Income tax expense |
5,012 |
|
|
7,068 |
|
|
14,872 |
|
|
70,803 |
|
Loss on sale of non-financial assets |
15 |
|
|
5 |
|
|
27 |
|
|
21 |
|
Total items not affecting cash |
51,035 |
|
|
60,580 |
|
|
169,700 |
|
|
205,040 |
|
|
|
|
|
|
|
|
|
Net change in non-cash working capital |
(7,287 |
) |
|
47,409 |
|
|
(52,974 |
) |
|
64,267 |
|
Contributions to pension and post-retirement benefit plans |
(1,154 |
) |
|
(2,241 |
) |
|
(3,418 |
) |
|
(7,439 |
) |
Provisions paid |
- |
|
|
(169 |
) |
|
(3,695 |
) |
|
(3,443 |
) |
Income tax payments, net |
(680 |
) |
|
(550 |
) |
|
(3,121 |
) |
|
(2,008 |
) |
Net cash from operating activities |
61,521 |
|
|
119,863 |
|
|
147,856 |
|
|
236,136 |
|
|
|
|
|
|
|
|
|
Cash flows from (used in) investing
activities |
|
|
|
|
|
|
|
Purchases of property, plant and equipment |
(7,857 |
) |
|
(5,993 |
) |
|
(15,821 |
) |
|
(14,673 |
) |
Purchases of property, plant and equipment and software |
|
|
|
|
|
|
|
related to the TAD Sherbrooke Project |
- |
|
|
(837 |
) |
|
- |
|
|
(1,580 |
) |
Purchases of property, plant and equipment related to the |
|
|
|
|
|
|
|
Sherbrooke Expansion Project |
(26,740 |
) |
|
(21,535 |
) |
|
(116,167 |
) |
|
(89,995 |
) |
Interest paid on credit facilities related to the Sherbrooke
Expansion |
|
|
|
|
|
|
|
Project |
(2,347 |
) |
|
(105 |
) |
|
(5,136 |
) |
|
(321 |
) |
Government assistance received |
- |
|
|
- |
|
|
- |
|
|
1,250 |
|
Purchases of software |
(7 |
) |
|
(48 |
) |
|
(294 |
) |
|
(556 |
) |
Proceeds on sale of property, plant and equipment |
- |
|
|
17 |
|
|
28 |
|
|
2,465 |
|
Net cash used in investing activities |
(36,951 |
) |
|
(28,501 |
) |
|
(137,390 |
) |
|
(103,410 |
) |
|
|
|
|
|
|
|
|
Cash flows from (used in) financing
activities |
|
|
|
|
|
|
|
Proceeds from long-term debt |
5,765 |
|
|
30,761 |
|
|
119,197 |
|
|
87,543 |
|
Repayment of long-term debt |
(11,852 |
) |
|
(46,337 |
) |
|
(33,045 |
) |
|
(69,906 |
) |
Payment of deferred financing fees |
(83 |
) |
|
(25 |
) |
|
(1,312 |
) |
|
(405 |
) |
Payment of lease liabilities |
(9,191 |
) |
|
(7,039 |
) |
|
(26,463 |
) |
|
(20,835 |
) |
Change in Restricted cash |
(1,183 |
) |
|
(1,380 |
) |
|
(32,381 |
) |
|
(3,937 |
) |
Interest paid on long-term debt |
(15,460 |
) |
|
(2,921 |
) |
|
(38,839 |
) |
|
(34,281 |
) |
Payment to related party |
- |
|
|
- |
|
|
(5,800 |
) |
|
(5,700 |
) |
Dividends paid, net |
(7,868 |
) |
|
(1,741 |
) |
|
(17,425 |
) |
|
(5,245 |
) |
Net cash used in financing activities |
(39,872 |
) |
|
(28,682 |
) |
|
(36,068 |
) |
|
(52,766 |
) |
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and
cash |
|
|
|
|
|
|
|
equivalents held in foreign currency |
(637 |
) |
|
220 |
|
|
1,089 |
|
|
(76 |
) |
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents during the
period |
(15,939 |
) |
|
62,900 |
|
|
(24,513 |
) |
|
79,884 |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - Beginning of
period |
127,154 |
|
|
88,245 |
|
|
135,728 |
|
|
71,261 |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - End of period |
111,215 |
|
|
151,145 |
|
|
111,215 |
|
|
151,145 |
|
|
|
|
|
|
|
|
|
Kruger Products Inc. |
Unaudited Segment and Geographic Results |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month period ended September 30, 2024 |
|
|
3-month period ended September 30, 2023 |
|
|
9-month period ended September 30, 2024 |
|
|
9-month period ended September 30, 2023 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
Segment Information |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment Revenue |
|
|
|
|
|
|
|
Consumer |
429,196 |
|
|
390,293 |
|
|
1,255,410 |
|
|
1,150,290 |
|
AFH |
91,889 |
|
|
83,106 |
|
|
254,907 |
|
|
240,403 |
|
|
|
|
|
|
|
|
|
Revenue from external customers |
521,085 |
|
|
473,399 |
|
|
1,510,317 |
|
|
1,390,693 |
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
|
|
|
|
|
|
|
Consumer |
62,414 |
|
|
65,925 |
|
|
185,373 |
|
|
170,468 |
|
AFH |
6,602 |
|
|
8,381 |
|
|
23,941 |
|
|
15,078 |
|
Corporate and other costs |
(3,351 |
) |
|
(1,924 |
) |
|
(11,291 |
) |
|
(8,159 |
) |
|
|
|
|
|
|
|
|
Total Adjusted EBITDA |
65,665 |
|
|
72,382 |
|
|
198,023 |
|
|
177,387 |
|
|
|
|
|
|
|
|
|
Reconciliation to net income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
28,300 |
|
|
25,337 |
|
|
82,988 |
|
|
73,576 |
|
Interest expense and other finance costs |
17,997 |
|
|
16,677 |
|
|
51,132 |
|
|
51,740 |
|
Loss (gain) on sale of property, plant and equipment |
- |
|
|
(11 |
) |
|
269 |
|
|
1,098 |
|
Loss on sale of non-financial assets |
15 |
|
|
5 |
|
|
27 |
|
|
21 |
|
Change in amortized cost of Partnership unit liability |
- |
|
|
- |
|
|
(881 |
) |
|
- |
|
Restructuring costs, net |
- |
|
|
77 |
|
|
219 |
|
|
1,300 |
|
Foreign exchange loss (gain) |
(5,266 |
) |
|
8,395 |
|
|
8,033 |
|
|
(870 |
) |
|
|
|
|
|
|
|
|
Income before income taxes |
24,619 |
|
|
21,902 |
|
|
56,236 |
|
|
50,522 |
|
|
|
|
|
|
|
|
|
Income tax expense |
5,012 |
|
|
7,068 |
|
|
14,872 |
|
|
70,803 |
|
|
|
|
|
|
|
|
|
Net income (loss) including non-controlling interest |
19,607 |
|
|
14,834 |
|
|
41,364 |
|
|
(20,281 |
) |
|
|
|
|
|
|
|
|
Geographic Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Canada |
282,222 |
|
|
267,588 |
|
|
827,363 |
|
|
793,533 |
|
US |
238,863 |
|
|
205,811 |
|
|
682,954 |
|
|
597,160 |
|
|
|
|
|
|
|
|
|
Total revenue |
521,085 |
|
|
473,399 |
|
|
1,510,317 |
|
|
1,390,693 |
|
|
|
|
|
|
|
|
|
KP Tissue Inc. |
Unaudited Condensed Statements of Financial
Position |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
September 30, 2024 |
|
|
December 31, 2023 |
|
|
$ |
|
|
$ |
|
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
|
Dividends receivable |
1,796 |
|
|
1,793 |
|
Income taxes recoverable |
367 |
|
|
652 |
|
Receivable from Investee |
65 |
|
|
- |
|
|
2,228 |
|
|
2,445 |
|
|
|
|
|
Non-current assets |
|
|
|
Investment in associate |
70,647 |
|
|
68,162 |
|
|
|
|
|
Total assets |
72,875 |
|
|
70,607 |
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
Dividend payable |
1,796 |
|
|
1,793 |
|
Payable to investee |
- |
|
|
457 |
|
Income taxes payable |
376 |
|
|
- |
|
|
|
|
|
Total liabilities |
2,172 |
|
|
2,250 |
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
Common shares |
22,702 |
|
|
22,560 |
|
Contributed surplus |
144,819 |
|
|
144,819 |
|
Deficit |
(113,398 |
) |
|
(115,027 |
) |
Accumulated other comprehensive income |
16,580 |
|
|
16,005 |
|
|
|
|
|
Total equity |
70,703 |
|
|
68,357 |
|
|
|
|
|
Total liabilities and equity |
72,875 |
|
|
70,607 |
|
|
|
|
|
KP Tissue Inc. |
Unaudited Condensed Statements of Income
(Loss) |
(thousands of Canadian dollars, except share and per share
amounts) |
|
|
|
|
|
|
|
|
|
3-month period ended September 30, 2024 |
|
|
3-month period ended September 30, 2023 |
|
|
9-month period ended September 30, 2024 |
|
|
9-month period ended September 30, 2023 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
|
|
|
|
|
|
|
Share of income (loss) |
2,259 |
|
|
1,789 |
|
|
4,758 |
|
|
(2,909 |
) |
Depreciation of fair value increments |
(278 |
) |
|
(286 |
) |
|
(847 |
) |
|
(886 |
) |
|
|
|
|
|
|
|
|
Equity income (loss) |
1,981 |
|
|
1,503 |
|
|
3,911 |
|
|
(3,795 |
) |
Dilution gain |
107 |
|
|
262 |
|
|
500 |
|
|
787 |
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
2,088 |
|
|
1,765 |
|
|
4,411 |
|
|
(3,008 |
) |
|
|
|
|
|
|
|
|
Deferred tax expense |
- |
|
|
- |
|
|
- |
|
|
3,892 |
|
|
|
|
|
|
|
|
|
Net income (loss) |
2,088 |
|
|
1,765 |
|
|
4,411 |
|
|
(6,900 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings (loss) per share |
0.21 |
|
|
0.18 |
|
|
0.44 |
|
|
(0.69 |
) |
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding |
9,979,383 |
|
|
9,957,841 |
|
|
9,973,463 |
|
|
9,953,646 |
|
|
|
|
|
|
|
|
|
KP Tissue Inc. |
Unaudited Condensed Statements of Cash Flows |
(thousands of Canadian dollars) |
|
|
|
|
|
|
|
|
|
3-month period ended September 30, 2024 |
|
|
3-month period ended September 30, 2023 |
|
|
9-month period ended September 30, 2024 |
|
|
9-month period ended September 30, 2023 |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
Cash flows from (used in) operating
activities |
|
|
|
|
|
|
|
Net income (loss) |
2,088 |
|
|
1,765 |
|
|
4,411 |
|
|
(6,900 |
) |
Items not affecting cash |
|
|
|
|
|
|
|
Equity loss (income) |
(1,981 |
) |
|
(1,503 |
) |
|
(3,911 |
) |
|
3,795 |
|
Dilution gain |
(107 |
) |
|
(262 |
) |
|
(500 |
) |
|
(787 |
) |
Deferred tax expense |
- |
|
|
- |
|
|
- |
|
|
3,892 |
|
Total items not affecting cash |
(2,088 |
) |
|
(1,765 |
) |
|
(4,411 |
) |
|
6,900 |
|
|
|
|
|
|
|
|
|
Decrease in payable to investee |
(376 |
) |
|
(137 |
) |
|
(660 |
) |
|
(137 |
) |
Tax refunds, net |
376 |
|
|
137 |
|
|
660 |
|
|
137 |
|
|
|
|
|
|
|
|
|
Net cash from (used in) operating activities |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
Dividends received, net |
1,743 |
|
|
1,739 |
|
|
5,239 |
|
|
5,242 |
|
|
|
|
|
|
|
|
|
Net cash from investing activities |
1,743 |
|
|
1,739 |
|
|
5,239 |
|
|
5,242 |
|
|
|
|
|
|
|
|
|
Cash flows used in financing activities |
|
|
|
|
|
|
|
Dividends paid, net |
(1,743 |
) |
|
(1,739 |
) |
|
(5,239 |
) |
|
(5,242 |
) |
|
|
|
|
|
|
|
|
Net cash used in financing activities |
(1,743 |
) |
|
(1,739 |
) |
|
(5,239 |
) |
|
(5,242 |
) |
|
|
|
|
|
|
|
|
Increase (decrease) in cash and cash equivalents during the
period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - Beginning of
period |
- |
|
|
- |
|
|
- |
|
|
- |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents - End of period |
- |
|
|
- |
|
|
- |
|
|
- |
|
KP Tissue (TSX:KPT)
Historical Stock Chart
From Oct 2024 to Nov 2024
KP Tissue (TSX:KPT)
Historical Stock Chart
From Nov 2023 to Nov 2024